Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
Stephen Bagley, Zev A. Binder, Lamia Lamrani, Eliana Marinari, Arati Desai, MacLean P. Nasrallah, Eileen Maloney, Steven Brem, Robert A. Lustig, Goldie Kurtz, Michelle Alonso‐Basanta, Pierre‐Emmanuel Bonté, Christel Goudot, Wilfrid Richer, Eliane Piaggio, Shawn Kothari, Léa Guyonnet, Coralie L. Guérin, Joshua J. Waterfall, Suyash Mohan, Wei‐Ting Hwang, Oliver Y. Tang, Meghan Logun, Meghna Bhattacharyya, Kelly Markowitz, Devora Delman, Amy Marshall, E. John Wherry, Sebastián Amigorena, Gregory L. Beatty, Jennifer L. Brogdon, Elizabeth O. Hexner, Denis Migliorini, Cécile Alanio, Donald M. O’Rourke
Topics & Concepts
PembrolizumabTolerabilityMedicineChimeric antigen receptorInternal medicineOncologyImmunotherapyEpidermal growth factor receptorImmunologyAdverse effectReceptorCancerCAR-T cell therapy researchAdvancements in Semiconductor Devices and Circuit DesignNanowire Synthesis and Applications